Cystic Fibrosis Foundation distributed the following clinical trial updates during the month of September. Click the trial title to get more details.
CFF issued the following alert on 09/01/2017.
Phase 2 study of LAU-7b in adults with CF (APPLAUD)
Status: Enrolling
Description: This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug LAU-7b and will use a placebo control.
Age: 12 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 50 to 90%
Number of Visits: 6
Length of Participation: 189 days
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03265288
CFF issued the following alert on 09/14/2017.
Phase 3 study of inhaled vancomycin in adults and children 6 years and older with cystic fibrosis
Status: Enrolling
Description: This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the inhaled drug vancomycin in adults and children 6 years and older with cystic fibrosis and positive cultures for methicillin-resistant Staphylococcus aureus (MRSA).
Age: 6 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 30 to 100%
Number of Visits: 8
Length of Participation: 12 months
ClinicalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT03181932?term=NCT03181932
CFF issued the following alert on 09/19/2017.
Phase 3 study of long-term ivacaftor in babies who have a CFTR gating mutation
Status: Enrolling
Description: This open-label study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of long-term ivacaftor in babies who have a CFTR gating mutation.
Age: 0 Days to 24 Months
Mutation: One Copy F508del or No Copies F508del
Fev1% Predicted: No FEV1 Limit
Number of Visits: 18
Length of Participation: 128 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03277196